Betty J. Dong, PharmD, FASHP
Patients with multidrug-resistant HIV will soon have a new drug option to try: ibalizumab-uiyk (Trogarzo, Theratechnologies and TaiMed), a humanized monoclonal antibody administered intravenously once every two weeks.
The medication, approved March 6 by the FDA and expected to be available in the second quarter, offers a novel option for some patients who may be dying from HIV, said Betty J. Dong, PharmD, FASHP, FAPHA, FCCP, AAHIVP, a professor of